FourKites’ Latest European Premier Carrier List Reflects ROI of High-quality Real-Time Supply Chain Visibility Data
23.9.2022 10:00:00 EEST | Business Wire | Press release
Leading real-time supply chain visibility provider FourKites today published its global Premier Carrier List (PCL), which recognises the rapidly growing community of brokers, carriers and 3PLs who are achieving the highest standards of visibility-related operational excellence across all modes of transport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220923005062/en/
FourKites’ Latest European Premier Carrier List Reflects ROI of High-quality Real-Time Supply Chain Visibility Data (Graphic: Business Wire)
To qualify for the PCL, carriers must demonstrate an ability to provide high-quality, consistent and accurate data on the vast majority of their shipments, thereby enabling their shipper customers and other ecosystem partners to streamline operations, increase the speed of shipping dock turn times, reduce inventory levels and optimise labour costs.
In the first half of 2022, 685 carriers were named to the PCL, which included an 8% increase for carriers based in Europe. These Premier Carriers demonstrated a significantly higher tracking percentage, on average, versus non-PCL carriers. Over the last six months, carriers who qualified for the Premier Carrier List tracked an average of 92.6% of their over-the-road shipments with real-time visibility, while non-PCL carriers tracked only 74.3% of their shipments.
“We partnered with FourKites because we wanted to grow our business,” says Vladas Stončius, CCO, Vlantana. “Increasingly, suppliers expect carriers to provide real-time data on all shipments. Thanks to FourKites, we’re able to do that efficiently and consistently, which has enabled us to win bigger customers and boost our margins.”
Notably, Premier Carriers witnessed higher growth rates than their non-PCL counterparts. In Europe, from H2 2021 to H1 2022, Premier Carriers experienced shipment volume growth of 9%, compared to non-PCL carriers in the region, who saw shipment volume contract 2%.
“Qualifying for FourKites’ Premier Carrier List is an increasingly important distinction for carriers, brokers and 3PLs who need to stand out in an increasingly competitive and volatile market,” said Jason Eversole, Vice President, Carrier Operations & Strategy, FourKites. “We’re pleased to see continued growth in the total number of Premier Carriers, and equally pleased to see the clear business benefits they are experiencing as a result of their visibility-related excellence.”
The Premier Carrier List is available here, where users can access and search the list according to carrier capabilities, transportation modes, geographies serviced and other relevant criteria.
Premier Carriers speak to program benefits:
"Transervice is honored to be recognised as a FourKites Premier Carrier. FourKites has enabled Transervice, and our clients, with unparalleled visibility into our logistics operations. This capability ensures complete transparency throughout the supply chain and promotes efficient resource utilisation. We are proud to partner with FourKites, and we look forward to their continued growth and innovation."
- Tom Poduch, Senior Director, Solutions, at Transervice
“Van den Bosch is always on the lookout for new opportunities to make its supply chain more efficient and sustainable. Fueled by data, insights and knowledge, innovation and digitalisation are key drivers. The qualification for Premier Carrier is a nice recognition and confirmation of our position as the supply changer in bulk.”
- Marrit Hopmans, Data & Applications Manager, Van den Bosch
“As a former employee of FourKites, I’ve experienced firsthand how imperative their technology is to the entire industry. TransLoop is extremely proud to be recognised as a FourKites Premier Carrier. We will continue to do whatever our shipper and carrier partners need us to do for TransLoop to be the most transparent and reliable broker partner in the industry.”
- Nick Reasoner, CEO, TransLoop
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.8 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,100 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit www.fourkites.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005062/en/
Contact information
Scott Johnston
European PR Director FourKites
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom